Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Cash from Financing Activities (2018 - 2025)

AdaptHealth (AHCO) has 8 years of Cash from Financing Activities data on record, last reported at -$32.9 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 38.98% year-over-year to -$32.9 million; the TTM value through Dec 2025 reached -$302.2 million, down 51.89%, while the annual FY2025 figure was -$302.2 million, 51.89% down from the prior year.
  • Cash from Financing Activities reached -$32.9 million in Q4 2025 per AHCO's latest filing, up from -$56.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $1.2 billion in Q1 2021 and bottomed at -$156.6 million in Q2 2025.
  • Average Cash from Financing Activities over 5 years is $47.0 million, with a median of -$20.7 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: surged 2007.94% in 2021, then plummeted 458.1% in 2024.
  • A 5-year view of Cash from Financing Activities shows it stood at -$21.7 million in 2021, then rose by 28.19% to -$15.6 million in 2022, then crashed by 181.32% to -$43.9 million in 2023, then dropped by 23.06% to -$54.0 million in 2024, then soared by 38.98% to -$32.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$32.9 million in Q4 2025, -$56.6 million in Q3 2025, and -$156.6 million in Q2 2025.